BC Cancer Trial Cuts Radiation Treatment Sessions by Over 90%

A groundbreaking clinical trial at BC Cancer Victoria is utilizing artificial intelligence (AI) to significantly reduce the number of radiation treatments for patients with prostate cancer. The trial has demonstrated the potential to cut treatment sessions by more than 90 percent, providing hope for improved patient outcomes and quality of life.

The initiative began in July 2025, focusing on patients diagnosed with localized prostate cancer, which is considered treatable. One participant, Mike Miles, received his diagnosis in January 2025 and faced the prospect of frequent appointments for radiation therapy. “The healthcare system is overwhelmed with old guys like me,” Miles remarked, reflecting on the challenges many patients face.

Traditionally, patients like Miles would undergo External Beam Radiation Therapy (EBRT), which often requires between 20 and 40 sessions. However, Dr. Abe Alexander, a radiation oncologist at BC Cancer Victoria, highlighted the limitations of this approach, noting that the radiation machine may lack precision in targeting the cancerous cells. This can lead to prolonged treatment schedules and increased stress for patients.

The new clinical trial combines Stereotactic Radiotherapy with AI technology, allowing for more accurate targeting of radiation beams. “This technology enables us to provide effective treatment while reducing the number of necessary sessions,” Dr. Alexander explained. Patients can potentially complete their treatment in just five sessions instead of the standard number.

AI plays a crucial role in this trial by minimizing radiation exposure to surrounding organs. During treatment, real-time data is provided to physicians, enabling them to make necessary adjustments on the fly. “The hope is that it would reduce side effects in the long run,” Dr. Alexander added.

Miles is among the first patients to experience this innovative treatment. After only two sessions, he reported a remarkable improvement in his health. His prostate-specific antigen (PSA) levels, which are vital for monitoring prostate health, dropped from 13 ng/ml to 1.3 ng/ml within a short time frame. The Canadian Cancer Society considers a normal PSA level to be around 4 ng/ml, indicating that Miles’ results are particularly promising.

The clinical trial aims to enhance the quality of life for patients by reducing the frequency of in-person visits to cancer treatment centers. Dr. Alexander emphasized the importance of alleviating the burden on patients, many of whom spend significant time managing their healthcare rather than enjoying life. To achieve this goal, participants in the trial are randomly assigned to receive either two or five treatment sessions.

Currently, approximately 15 to 20 patients have enrolled in the trial, which is set to expand to residents on the Mainland in Summer 2026. The trial aims to include a total of 100 patients and is expected to conclude within two years, paving the way for further advancements in cancer treatment.

This innovative approach to prostate cancer treatment at BC Cancer Victoria not only highlights the potential of AI in healthcare but also reflects a growing commitment to improving patient experiences and outcomes. As clinical trials progress, the hope is to provide more effective care with fewer disruptions to patients’ lives.